| Lee, Mark C |
NCT05372419: A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color |
|
|
| Active, not recruiting | 3 | 80 | US | Lebrikizumab, LY3650150, DRM06 | Eli Lilly and Company | Atopic Dermatitis | 05/24 | 02/25 | | |
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) |
|
|
| Recruiting | 3 | 12500 | Europe, Canada, Japan, US, RoW | Lepodisiran Sodium, LY3819469, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a) | 03/29 | 03/29 | | |
SCALP1, NCT05910450: A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss |
|
|
| Recruiting | 3 | 726 | US, RoW | Clascoterone 5% solution, CB-03-01 5% solution, Vehicle solution, Vehicle | Cassiopea SpA, Ergomed PLC, Pharmapace Inc, Canfield Scientific Inc., ICON Clinical Research | Alopecia, Androgenetic | 10/24 | 04/25 | | |
| Recruiting | 3 | 1300 | Europe, Canada, Japan, US, RoW | TAK-279 | Takeda | Plaque Psoriasis | 05/26 | 05/26 | | |
TOGETHER-PsO, NCT06588283: Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight |
|
|
| Recruiting | 3 | 250 | US | Ixekizumab, LY2439821, Tirzepatide, LY3298176 | Eli Lilly and Company | Psoriasis, Obesity | 12/25 | 05/26 | | |
NCT06088043: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment |
|
|
| Active, not recruiting | 3 | 693 | Europe, Canada, Japan, US, RoW | TAK-279, Placebo, Apremilast | Takeda | Plaque Psoriasis | 08/25 | 04/26 | | |
NCT05772520: The Efficacy and Safety of TLL018 in Moderate-to-severe Plaque Psoriasis |
|
|
| Completed | 2 | 82 | US | TLL018 tablets, TLL018 Placeboes | Hangzhou Highlightll Pharmaceutical Co., Ltd | Plaque Psoriasis | 12/24 | 12/24 | | |
NCT05911841: A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis |
|
|
| Active, not recruiting | 2 | 236 | Europe, Canada, Japan, US, RoW | LY3454738, Placebo | Eli Lilly and Company | Atopic Dermatitis | 06/25 | 03/26 | | |
CALM-CSU, NCT06077773: Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria |
|
|
| Recruiting | 2 | 154 | Europe, Canada, US | Oral EP262, Placebo | Escient Pharmaceuticals, Inc | Chronic Spontaneous Urticaria | 06/25 | 07/25 | | |
NCT06119529: A Study of LY3872386 in Healthy Participants and Participants With Atopic Dermatitis |
|
|
| Terminated | 1 | 18 | US | LY3872386, Prednisone, Placebo | Eli Lilly and Company | Healthy, Atopic Dermatitis | 04/24 | 04/24 | | |
| Zhang, Yi |
NCT05003245: Compare the Efficacy and Safety of HLX04-O With Ranibizumab in Subjects With wAMD |
|
|
| Recruiting | 3 | 388 | RoW | HLX04-O，recombinant anti-vascular endothelial growth factor (VEGF) humanized monoclonal antibody ophthalmic injection, Lucentis | Shanghai Henlius Biotech | Age Related Macular Degeneration | 08/23 | 03/24 | | |
nAMD, NCT05461339: TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular Degeneration |
|
|
| Active, not recruiting | 3 | 488 | RoW | TAB014 Monoclonal Antibody Injection, TAB014, Ranibizumab Injection [Lucentis], Lucentis | TOT Biopharm Co., Ltd., Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. | Neovascular Age-related Macular Degeneration | 09/24 | 02/25 | | |
NCT06300177: D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure |
|
|
| Recruiting | 3 | 522 | RoW | D-1553 Tablet, Docetaxel injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Non Small Cell Lung Cancer | 10/26 | 12/27 | | |
NCT06419621: PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic Triple-negative Breast Cancer |
|
|
| Recruiting | 3 | 360 | RoW | PM8002, Nab-Paclitaxel, Placebo | Biotheus Inc. | Triple Negative Breast Cancer(TNBC) | 07/27 | 07/28 | | |
RC48-C006, NCT03500380: A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases |
|
|
| Active, not recruiting | 2/3 | 301 | RoW | RC48-ADC, RC48, Lapatinib, Capecitabine | RemeGen Co., Ltd. | Breast Neoplasms, Breast Diseases, Capecitabine, HER2-positive Breast Cancer, HER2 Positive Breast Carcinoma, HER2-positive Advanced Breast With Liver Metastases | 07/24 | 12/24 | | |
NCT04398940: A Study of TQ-B3139 Capsules in Subjects With MET-Altered Advanced Non-small Cell Lung Cancer |
|
|
| Recruiting | 2 | 71 | RoW | TQ-B3139 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Non Small Cell Lung Cancer | 01/22 | 10/22 | | |
NCT03638206: Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies |
|
|
| Recruiting | 1/2 | 73 | RoW | CAR-T cell immunotherapy | Shenzhen BinDeBio Ltd., The First Affiliated Hospital of Zhengzhou University | B-cell Acute Lymphoblastic Leukemia, Lymphoma, Myeloid Leukemia, Multiple Myeloma, Hepatoma, Gastric Cancer, Pancreatic Cancer, Mesothelioma, Colorectal Cancer, Esophagus Cancer, Lung Cancer, Glioma, Melanoma, Synovial Sarcoma, Ovarian Cancer, Renal Carcinoma | 03/23 | 03/23 | | |
NCT05117138: Safety and Efficacy of Chimeric Antigen Receptor T Lymphocytes for Patients With Intermediate and Advanced Tumors |
|
|
| Not yet recruiting | 1/2 | 39 | RoW | AMT-116 CAR-T cells, AMT-253 CAR-T cells | Beijing Immunochina Medical Science & Technology Co., Ltd. | Melanoma, Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma | 12/23 | 03/24 | | |
NCT06316791: Exploratory Clinical Study of CNCT19 Anti CD19 Cell Therapy in the Treatment of Refractory Autoimmune Diseases |
|
|
| Recruiting | 1 | 24 | RoW | single dose of CNCT19 | Juventas Cell Therapy Ltd. | Lupus Erythematosus, Systemic | 12/24 | 12/25 | | |
NCT05122221: CRTE7A2-01 TCR-T Cell for HPV-16 Positive Advanced Cervical, Anal, or Head and Neck Cancers |
|
|
| Recruiting | 1 | 12 | RoW | Fludarabine + Cyclophosphamide, Interleukin-2, CRTE7A2-01 TCR-T Cell | Corregene Biotechnology Co., Ltd | Cervical Cancer, Anal Cancer, Head and Neck Cancers | 03/23 | 12/24 | | |
NCT06152757: BGT007H Cells for the Treatment of Recurrent/Refractory Gastrointestinal Tumors |
|
|
| Recruiting | 1 | 14 | RoW | First dose, Second dose, The third dose, The fourth dose | BioSyngen Pte Ltd, The First Affiliated Hospital of Zhengzhou University | Gastrointestinal Tumors | 07/25 | 07/27 | | |
NCT05381181: Safety and Efficacy Evaluation of Next-generation CD19-UCART |
|
|
| Not yet recruiting | 1 | 20 | NA | CD19-UCART | Bioray Laboratories, The First Affiliated Hospital of Zhengzhou University | Acute Lymphoblastic Leukemia, Non Hodgkin Lymphoma | 05/24 | 05/26 | | |
NCT06077903: GT101 Injection in the Treatment of Metastatic/Recurrent Advanced Solid Tumors |
|
|
| Recruiting | 1 | 20 | RoW | GT101 | Grit Biotechnology | Adult | 07/24 | 07/24 | | |
NCT06548620: A Study of RD06-04 in Patients With Active Autoimmune Diseases |
|
|
| Not yet recruiting | 1 | 18 | RoW | RD06-04 cell infusion | Nanjing Bioheng Biotech Co., Ltd. | SLE (Systemic Lupus), Sclerosis, ANCA Associated Vasculitis, IIM, SS, MS, NMO Spectrum Disorder, MG | 08/26 | 08/27 | | |
NCT06094426: Autologous Tumor Infiltrating Lymphocyte Injection for the Treatment of Advanced Solid Tumors |
|
|
| Recruiting | 1 | 30 | RoW | GT316 | Grit Biotechnology | Solid Tumor, Adult, GT316 | 02/26 | 02/26 | | |
NCT03908671: Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Patients With Advanced Esophageal Cancer and Non-small Cell Lung Cancer |
|
|
| Recruiting | N/A | 24 | RoW | Personalized mRNA Tumor Vaccine | Stemirna Therapeutics, The First Affiliated Hospital of Zhengzhou University | Esophageal Cancer, Non Small Cell Lung Cancer | 10/24 | 12/25 | | |
NCT06658951: Anti-HER2 CAR-T Cell Injection in Patients With HER2-positive Advanced Malignant Solid Tumors |
|
|
| Not yet recruiting | N/A | 30 | RoW | Anti-HER2 CAR-T cells | UTC Therapeutics Inc., The First Affiliated Hospital of Zhengzhou University | HER2-positive Advanced Malignant Solid Tumors | 11/26 | 11/27 | | |
NCT05308875: Efficacy and Safety Evaluation of PD1-BCMA-CART |
|
|
| Not yet recruiting | N/A | 9 | RoW | PD1-BCMA-CART | Bioray Laboratories, The First Affiliated Hospital of Zhengzhou University | Multiple Myeloma | 01/25 | 10/25 | | |
| Recruiting | N/A | 1000 | US | MicroVention Mechanical Thrombectomy Devices as first-line treatment | Microvention-Terumo, Inc. | Acute Ischemic Stroke, Vessel Occlusion, Stroke, Ischemic | 12/25 | 12/25 | | |
NCT05409989: MicroVention, Inc. Flow Re-Direction Endoluminal Device X (FRED™ X™) Post-Approval Study |
|
|
| Recruiting | N/A | 154 | US | FRED™ X™, Flow Re-Direction Endoluminal Device X | Microvention-Terumo, Inc. | Intracranial Aneurysm | 09/29 | 11/29 | | |
| Xu, Gang |
| Suspended | 2 | 279 | Europe, US, RoW | zetomipzomib, KZR-616, placebo, matching placebo | Kezar Life Sciences, Inc. | Lupus Nephritis | 05/26 | 07/26 | | |
| Davis, Steven A |
NCT05372419: A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color |
|
|
| Active, not recruiting | 3 | 80 | US | Lebrikizumab, LY3650150, DRM06 | Eli Lilly and Company | Atopic Dermatitis | 05/24 | 02/25 | | |
| Recruiting | 3 | 1300 | Europe, Canada, Japan, US, RoW | TAK-279 | Takeda | Plaque Psoriasis | 05/26 | 05/26 | | |
TOGETHER-PsO, NCT06588283: Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight |
|
|
| Recruiting | 3 | 250 | US | Ixekizumab, LY2439821, Tirzepatide, LY3298176 | Eli Lilly and Company | Psoriasis, Obesity | 12/25 | 05/26 | | |
TAK-279-3002, NCT06108544: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period |
|
|
| Active, not recruiting | 3 | 1108 | Europe, Canada, US, RoW | TAK-279, Placebo, Apremilast | Takeda | Plaque Psoriasis | 12/24 | 11/25 | | |
NCT06163404: Open-Label Study to Evaluate the Safety and Effectiveness of the Spirair Implant |
|
|
| Recruiting | N/A | 50 | US | Implantation of Spirair Nasal Device using the Spirair delivery system., SeptAlign | Spirair, Inc | Nasal Septal Deviation, Nasal Airway Obstruction | 12/24 | 07/25 | | |
NCT06477172: Autologous Hair Follicle Derived Secretome as Adjunct to Aesthetic Procedures |
|
|
| Recruiting | N/A | 500 | Canada, US | | Acorn Biolabs Inc. | Post Procedural Erythema | 02/25 | 02/25 | | |
| Yuan, Xianglin |
NCT03236649: The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects |
|
|
| Terminated | 3 | 89 | RoW | Icaritin, Sorafenib Tosylate Tablets | Beijing Shenogen Biomedical Co., Ltd, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Eastern Theater General Hospital,QinHuai District Medical Area, Peking University Cancer Hospital & Institute, Chinese PLA General Hospital, Beijing Hospital, General Hospital of Chinese Armed Police Forces, Guang'anmen Hospital of China Academy of Chinese Medical Sciences, Jinan Central Hospital, Linyi Cancer Hospital, The First Affiliated Hospital of Anhui Medical University, Anhui Provincial Hospital, The First Affiliated Hospital with Nanjing Medical University, The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China, Nanfang Hospital of Southern Medical University, First People's Hospital of Foshan, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Tianjin Medical University Cancer Institute and Hospital, The Fourth Hospital of Hebei Medical University, Hunan Cancer Hospital, The First Hospital of Jilin University, 307 Hospital of PLA, Fudan University, Henan Cancer Hospital, Jilin Provincial Tumor Hospital, First Affiliated Hospital of Harbin Medical University, First Affiliated Hospital Bengbu Medical College, The First Affiliated Hospital of Soochow University, Tongji Hospital, Beijing YouAn Hospital | Hepatocellular Carcinoma (HCC) | 02/22 | 02/22 | | |
NCT04714190: A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression |
|
|
| Recruiting | 3 | 351 | RoW | RC48-ADC, Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection, Paclitaxel injection, Taxol, Irinotecan Hydrochloride Injection, CAMPTO, Apatinib Mesylate Tablets, Aitan | RemeGen Co., Ltd. | Gastric Cancer, HER2 Overexpressing Gastric Carcinoma | 12/24 | 06/25 | | |
GAPSO, NCT03801668: Albumin-bound Paclitaxel Plus S-1 Versus SOX as First-line Treatment in Advanced or Recurrent Gastric Adenocarcinoma |
|
|
| Recruiting | 3 | 294 | RoW | Albumin-bound Paclitaxel plus S-1, Oxaliplatin plus S-1 | Huazhong University of Science and Technology, CSPC Ouyi Pharmaceutical Co., Ltd. | Gastric Cancer | 12/22 | 03/23 | | |
NCT04385550: A Study of Anlotinib Hydrochloride Capsule Combined With AK105 Injection in Subject With Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma |
|
|
| Not yet recruiting | 3 | 528 | RoW | Anlotinib hydrochloride capsule, AK105 injection, Paclitaxel injection, Docetaxel injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma | 10/23 | 12/23 | | |
NAUTICALCRC, NCT05004350: A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer. |
|
|
| Active, not recruiting | 2 | 103 | RoW | Encorafenib, Braftovi®, PF-07263896, W0090, LGX818, ONO-7702, Cetuximab, Erbitux®, C225, FOLFIRI, Folinic acid + Fluorouracil + Irinotecan | Pierre Fabre Medicament, Merck KGaA, Darmstadt, Germany | BRAF V600E, Metastatic Colorectal Cancer | 12/23 | 01/25 | | |
NCT03941574: A Clinical Study to Evaluate HLX10 Monotherapy for the Treatment of MSI-H or dMMR Solid Tumors That Failed to Respond to Standard Therapy |
|
|
| Recruiting | 2 | 108 | RoW | HLX10 | Shanghai Henlius Biotech | MSI-H Solid Malignant Tumor | 05/24 | 06/26 | | |
NCT06632262: A Phase 2 Clinical Study of ABSK061 and ABSK043 |
|
|
| Not yet recruiting | 2 | 202 | RoW | ABSK061 + ABSK043, ABSK061+ABSK043 in combination with CAPOX | Abbisko Therapeutics Co, Ltd | HER2-Gastric/Gastroesophageal Junction Cancer, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Solid Tumors | 11/29 | 06/30 | | |
NCT05934331: A LM-302 Combined With Toripalimab Phase II Study |
|
|
| Recruiting | 2 | 276 | RoW | LM302+Toripalimab, LM302+JS001 | LaNova Medicines Zhejiang Co., Ltd. | Gastric Cancer, Pancreatic Cancer | 07/25 | 01/26 | | |
CT041-ST-01, NCT04581473: Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection |
|
|
| Recruiting | 1/2 | 192 | RoW | CT041 autologous CAR T-cell injection, CAR T-cell injection, Physician's Choice（Paclitaxel or Irinotecan or Apatinib or Anti-PD-1 antibody）, Best support care(BSC) | CARsgen Therapeutics Co., Ltd., Peking University Cancer Hospital & Institute, Fudan University | Gastric Adenocarcinoma, Pancreatic Cancer, Gastroesophageal Junction Adenocarcinoma | 06/24 | 06/38 | | |
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies |
|
|
| Recruiting | 1/2 | 1300 | Canada, US, RoW | SKB264 | Klus Pharma Inc. | Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer | 08/25 | 07/26 | | |
KYM901, NCT04805307: Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901 |
|
|
| Recruiting | 1 | 162 | RoW | CMG901 | Keymed Biosciences Co.Ltd | Advanced Solid Tumor, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Pancreatic Cancer | 05/24 | 10/24 | | |
CIBI343A101, NCT05458219: A First-in-human Study of IBI343 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors |
|
|
| Recruiting | 1 | 470 | US, RoW | IBI343 | Innovent Biologics (Suzhou) Co. Ltd., Innovent Biologics, Inc., TigerMed | Locally Advanced Unresectable or Metastatic Solid Tumors | 12/25 | 12/25 | | |
| Chen, Yuan |
| Recruiting | 1/2 | 280 | RoW | SAF-189s, foritinib succinate | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Advanced Cancer, Advanced Solid Tumor, Lung Cancer, Nonsmall Cell | 12/22 | 03/26 | | |
NCT04993391: AP-L1898 Capsule in Patients With Non-small Cell Lung Cancer |
|
|
| Recruiting | 1/2 | 156 | RoW | JS111(AP-L1898 Capsules) | Suzhou Junjing BioSciences Co., Ltd. | Lung Cancer | 06/24 | 08/24 | | |
| An, Ping |
| Recruiting | 3 | 612 | Europe, Canada, US, RoW | ABX464, Obefazimod, Placebo | Abivax S.A. | Ulcerative Colitis | 03/25 | 04/25 | | |
NCT05181137 / 2021-001940-86: A Phase 3 Study to Investigate the Efficacy and Safety of SHR0302 With Moderately to Severely Active Ulcerative Colitis |
|
|
| Recruiting | 3 | 368 | Europe, US, RoW | SHR0302, Placebo | Reistone Biopharma Company Limited, Reistone Biopharma Company Limited | Ulcerative Colitis | 10/24 | 03/25 | | |
| Recruiting | 3 | 1050 | Europe, Canada, Japan, US, RoW | ABX464, Obefazimod, Placebo | Abivax S.A. | Ulcerative Colitis | 01/26 | 01/30 | | |
NCT05837897: A Study of Vedolizumab in Adult Participants With Moderate to Severe Crohn's Disease |
|
|
| Recruiting | 3 | 408 | RoW | Vedolizumab IV, Placebo | Takeda | Crohn's Disease | 03/30 | 05/31 | | |
TQH3906-Ib-01, NCT06754891: Clinical Trial of TQH3906 Capsules for the Treatment of Adult Patients With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease |
|
|
| Not yet recruiting | 1 | 116 | RoW | TQH3906 capsules | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Inflammatory Bowel Diseases | 12/26 | 12/27 | | |
| Contact, Site Public |
| Completed | 4 | 50 | RoW | ADVATE | Baxalta now part of Shire, Takeda Development Center Americas, Inc. | Hemophilia A | 02/23 | 02/23 | | |
SWITCH, NCT04718779: A Study of Enzyme Replacement Therapy (VPRIV) in People With Type 1 Gaucher Disease Who Were Previously Treated With Substrate Reduction Therapy |
|
|
| Completed | 4 | 4 | US | Digital Engagement Application (GD App), No Intervention | Takeda | Gaucher Disease | 02/23 | 02/23 | | |
| Active, not recruiting | 4 | 200 | US | CDPATH™, PROSPECT, Blood Draw | Takeda | Crohn's Disease | 10/25 | 06/26 | | |
| Recruiting | 4 | 80 | RoW | Leuprorelin Acetate Depot 3M, Leuprolide acetate Depot 3M | Takeda, Takeda | Central Precocious Puberty | 05/25 | 05/25 | | |
| Completed | 4 | 5 | RoW | Elaprase, Idursulfase | Takeda, Takeda Biopharmaceuticals India Pvt. Ltd. | Hunter Syndrome | 04/24 | 04/24 | | |
NCT05442554: A Study of Brentuximab Vedotin Treatment in Chinese Adults With CD30-Positive Cutaneous T-Cell Lymphoma |
|
|
| Completed | 4 | 10 | RoW | Brentuximab vedotin, SGN-35 | Takeda | T-Cell Lymphoma | 08/24 | 08/24 | | |
NCT05067868: A Study of Replagal in Children and Adults With Fabry Disease in India |
|
|
| Active, not recruiting | 4 | 5 | RoW | Replagal | Shire | Fabry Disease | 10/26 | 11/26 | | |
| Active, not recruiting | 4 | 288 | Europe, US | Guanfacine hydrochloride (TAK-503), Intuniv, SPD503, Atomoxetine hydrochloride, Placebo | Shire, Takeda Development Center Americas, Inc. | Attention Deficit Hyperactivity Disorder | 06/27 | 06/27 | | |
| Active, not recruiting | 4 | 50 | Europe, RoW | Darvadstrocel, Alofisel, Cx601 | Takeda, Takeda Development Center Americas, Inc. | Crohn's Disease, Complex Perianal Fistula | 03/26 | 03/26 | | |
NCT05494593: A Study of ELAPRASE in Treatment-naïve Participants With Hunter Syndrome (Mucopolysaccharidosis [MPS] II) |
|
|
| Recruiting | 4 | 5 | US | ELAPRASE, Idursulfase, Rituximab, Methotrexate, Intravenous Immunoglobulin (IVIG) | Takeda, Takeda Development Center Americas, Inc. | Mucopolysaccharidosis (MPS), Hunter Syndrome | 07/28 | 07/28 | | |
NCT06045754: A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease |
|
|
| Recruiting | 4 | 150 | Canada, US | Vedolizumab, Entyvio, Adalimumab, Humira, Ustekinumab, Stelara | Takeda | Crohn's Disease | 06/27 | 06/27 | | |
NCT06095128: A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC) |
|
|
| Recruiting | 4 | 65 | Canada, US | Vedolizumab, Entyvio, MLN0002, Tofacitinib, Xeljanz, CP-690, CP-550 | Takeda | Ulcerative Colitis | 07/27 | 07/27 | | |
| Active, not recruiting | 3 | 245 | Europe, Canada, Japan, US, RoW | Ponatinib, Iclusig, Imatinib, Gleevec, Vincristine, Dexamethasone, Cytarabine, Methotrexate, Prednisone | Takeda | Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) | 08/22 | 07/27 | | |
|
|
| Terminated | 3 | 17 | Europe, Canada | REPLAGAL, SHP675 | Shire | Fabry Disease | 12/22 | 12/22 | | |
NCT04444895 / 2019-004823-20: A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor |
|
|
| Completed | 3 | 73 | Europe, Canada, Japan, US | Lanadelumab, DX-2930, SHP643, TAK-743 | Shire, Takeda Development Center Americas, Inc. | Angioedema | 05/23 | 05/23 | | |
| Completed | 3 | 51 | Europe, Japan, US | BAX930, rADAMTS13, SHP-655, TAK-755, recombinant ADAMTS13, BAX 930, Standard of care | Baxalta now part of Shire, Takeda Development Center Americas, Inc. | Thrombotic Thrombocytopenic Purpura (TTP) | 12/23 | 05/24 | | |
NCT03879135 / 2018-003453-16: A Study of Recombinant Von Willebrand Factor (rVWF) in Pediatric and Adult Participants With Severe Von Willebrand Disease (VWD) |
|
|
| Active, not recruiting | 3 | 38 | Europe, US, RoW | rVWF, Vonvendi, Vonicog alfa, rFVIII, Octocog alfa, ADVATE | Baxalta now part of Shire, Takeda Development Center Americas, Inc. | Von Willebrand Disease (VWD) | 03/25 | 03/25 | | |
| Completed | 3 | 270 | Europe, Canada, Japan, US, RoW | Placebo, Soticlestat, TAK-935 | Takeda | Lennox Gastaut Syndrome (LGS) | 01/24 | 01/24 | | |
NCT06165341: Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis) |
|
|
| Recruiting | 3 | 50 | Europe, Canada, US | Fazirsiran Injection, TAK-999, ARO-AAT, ADS-001, Placebo | Takeda | Alpha1-Antitrypsin Deficiency | 08/28 | 08/28 | | |
NCT02932618 / 2016-001477-33: A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD) |
|
|
| Recruiting | 3 | 34 | Europe, US, RoW | von Willebrand factor (Recombinant), VONVENDI, rVWF, BAX111, BAX 111, Antihemophilic Factor (Recombinant), ADVATE, Recombinant Factor VIII, rFVIII | Baxalta now part of Shire, Takeda Development Center Americas, Inc. | Von Willebrand Disease | 01/25 | 01/25 | | |
| Completed | 3 | 144 | Europe, Canada, Japan, US, RoW | Soticlestat, TAK-935, Placebo | Takeda | Dravet Syndrome (DS) | 04/24 | 04/24 | | |
TAK-935-3004, NCT06422377: A Study Evaluating Soticlestat in Participants With Dravet Syndrome or Lennox-Gastaut Syndrome Who Have Been Exposed to Fenfluramine |
|
|
| Terminated | 3 | 1 | Europe | Soticlestat, TAK-935 | Takeda | Dravet Syndrome (DS), Lennox-Gastaut Syndrome (LGS) | 08/24 | 08/24 | | |
| Completed | 3 | 20 | RoW | REPLAGAL, Agalsidase Alfa, TAK-675 | Takeda, Takeda Development Center Americas, Inc | Fabry Disease | 01/24 | 01/24 | | |
| Completed | 3 | 20 | RoW | Lanadelumab, SHP643, TAKHZYRO, TAK-743, DX-2930, Lanadelumab Injection | Takeda, Takeda | Hereditary Angioedema (HAE) | 11/23 | 11/23 | | |
| Recruiting | 3 | 1300 | Europe, Canada, Japan, US, RoW | TAK-279 | Takeda | Plaque Psoriasis | 05/26 | 05/26 | | |
Vedolizumab-3041, NCT06443502: A Study to Learn About the Safety of Vedolizumab and How Well it Works in Children and Teenagers With Active Chronic Pouchitis |
|
|
| Recruiting | 3 | 30 | Europe, RoW | Vedolizumab, Entyvio, MLN0002, Kynteles, Concomitant Antibiotic Therapy | Takeda | Pouchitis | 12/29 | 12/29 | | |
| Active, not recruiting | 3 | 480 | RoW | TDV, TAK-003, Placebo | Takeda, Takeda | Healthy Volunteers | 05/25 | 05/25 | | |
| Recruiting | 3 | 120 | Europe, Canada, Japan, US, RoW | Vedolizumab IV, ENTYVIO, KYNTELES, MLN0002 | Takeda, Takeda Development Center Americas, Inc. | Crohn's Disease (CD) | 11/24 | 11/24 | | |
| Completed | 3 | 20 | RoW | Velaglucerase Alfa, VPRIV | Takeda, Takeda | Gaucher Disease | 08/24 | 08/24 | | |
NCT05707351: A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Severe Hemophilia A |
|
|
| Completed | 3 | 37 | RoW | Adynovate, Antihemophilic Factor (recombinant) PEGylated, Rurioctocog Alfa Pegol | Takeda | Hemophilia A | 09/24 | 09/24 | | |
| Recruiting | 3 | 396 | Canada, US | Vedolizumab, Entyvio, MLN0002, KYNTELES, Upadacitinib, Rinvoq, Placebo | Takeda | Crohn's Disease | 06/27 | 08/28 | | |
NCT06439342: A Study of Maribavir in Chinese Adults With Cytomegalovirus (CMV) Infections |
|
|
| Not yet recruiting | 3 | 20 | RoW | Maribavir, TAK-620 | Takeda | Cytomegalovirus (CMV) | 02/27 | 02/27 | | |
SWOG S2302, NCT05633602: Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study |
|
|
| Recruiting | 3 | 700 | US | Chemotherapy, Chemo, Chemotherapy (NOS), Chemotherapy, Cancer, General, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Ramucirumab, Anti-VEGFR-2 Fully Human Monoclonal Antibody IMC-1121B, Cyramza, IMC-1121B, LY3009806 | SWOG Cancer Research Network, National Cancer Institute (NCI), Eli Lilly and Company, Merck Sharp & Dohme LLC | Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 | 03/25 | 03/28 | | |
| Recruiting | 3 | 20 | Europe, Japan, RoW | Darvadstrocel, Cx601 | Takeda, Takeda Development Center Americas, Inc. | Crohn's Disease, Complex Perianal Fistula | 06/25 | 12/25 | | |
| Recruiting | 3 | 288 | Europe, Canada, US, RoW | RYZ101, Everolimus, Sunitinib, Octreotide, Lanreotide | RayzeBio, Inc., RayzeBio, Inc. | GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors, Carcinoid, Carcinoid Tumor, Pancreatic NET | 12/25 | 07/28 | | |
TAK-279-3002, NCT06108544: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period |
|
|
| Active, not recruiting | 3 | 1108 | Europe, Canada, US, RoW | TAK-279, Placebo, Apremilast | Takeda | Plaque Psoriasis | 12/24 | 11/25 | | |
NCT06088043: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment |
|
|
| Active, not recruiting | 3 | 693 | Europe, Canada, Japan, US, RoW | TAK-279, Placebo, Apremilast | Takeda | Plaque Psoriasis | 08/25 | 04/26 | | |
| Active, not recruiting | 3 | 121 | Europe, Canada, Japan, US, RoW | Vedolizumab, MLN0002, ENTYVIO, KYNTELES | Takeda, Takeda Development Center Americas, Inc. | Colitis, Ulcerative | 08/25 | 08/25 | | |
| Terminated | 3 | 175 | US | Prucalopride, TAK-555, Prucalopride succinate, Placebo | Takeda, Takeda Development Center Americas, Inc. | Constipation | 11/23 | 11/23 | | |
| Recruiting | 3 | 328 | Europe, Canada, US | TAK-330, SOC 4F-PCC | Takeda, Takeda Development Center Americas, Inc. | Coagulation Disorder | 04/28 | 04/28 | | |
| Recruiting | 3 | 400 | Europe, Canada, Japan, US, RoW | Soticlestat, TAK-935 | Takeda | Dravet Syndrome (DS), Lennox Gastaut Syndrome (LGS) | 05/26 | 05/26 | | |
NCT04683003: A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura |
|
|
| Recruiting | 3 | 77 | Europe, Japan, US, RoW | TAK-755, rADAMTS13; recombinant ADAMTS13; SHP-655; BAX 930 | Takeda, Takeda Development Center Americas, Inc., Shire | Thrombotic Thrombocytopenic Purpura (TTP) | 03/27 | 03/27 | | |
TAK-620-2004, NCT05319353 / 2021-004279-15: A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT) |
|
|
| Active, not recruiting | 3 | 80 | Europe, Japan, US, RoW | Maribavir, TAK-620 | Takeda, Takeda Development Center Americas, Inc. | Cytomegalovirus (CMV) | 01/27 | 01/27 | | |
NCT04969731: Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer |
|
|
| Recruiting | 3 | 408 | RoW | Immuncell-LC, Autologous activated T lymphocyte, Gemcitabine | GC Cell Corporation | Pancreatic Ductal Adenocarcinoma | 12/26 | 06/27 | | |
